Congressman Cárdenas’ tour and visit exemplifies CLSA’s efforts to provide premier educational opportunities to policymakers and thought leaders in Washington, Sacramento and locally. | READ MORE »
Numerous Bills Of Note Poised To Move Quickly As The California Legislature Returns | READ MORE »
Governor Brown Signs CLSA-Sponsored Bill Into Law To Protect Diabetes Patients | READ MORE »
New City And County Legislative Efforts On Polystyrene | READ MORE »
The addition of Collora enhances Hogan Lovells’ capabilities to serve clients in one of the most dynamic and growing markets in the US. | READ MORE »
NexGeneGirls Bootcamp and Summer Academy | READ MORE »
California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, LinkedIn, and YouTube.
California’s Life Sciences Community Celebration Overflows at CLSA’s Statewide Open Houses
August 24, 2017
As the statewide advocacy and business leadership trade association representing life sciences in California – the global leader for life sciences innovation and the sixth largest economy in the world – the work CLSA does connects and strengthens the entire life sciences community across our great state. With boots on the ground in Washington DC, Sacramento, the Bay Area, Los Angeles and San Diego, CLSA takes every opportunity to work with industry, government, academia, patients and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy.
The last week of July and the first week of August saw more than 700 members of CLSA and the California life sciences community gather to celebrate CLSA’s Annual Anniversary & Open House celebrations in South San Francisco and San Diego. The open houses allowed CLSA to celebrate the 40 year legacy from BayBio/CHI merger, highlight the many benefits available to CLSA members, and provide an opportunity for the California life sciences community to connect.
On July 26, attendees flocked to CLSA’s expansive South San Francisco Open House to network, enjoy local wine and beer, sample food truck delicacies, learn more about valuable purchasing programs – from partners like VWR, the CLSA Employee Benefits Trust, UPS, ShareVault and others – and win fabulous raffle prizes supplied by our member benefit partners. Click here to check out photos from the South San Francisco open house.
One week later, CLSA hosted hundreds of attendees for our tropical-themed Open House in San Diego at the beautiful facility of CLSA member JLABS. CLSA kicked off the event by hosting a tour of San Diego life sciences companies and an innovation roundtable between Congressman Tony Cárdenas and local life sciences executives. Interested members took tours of the JLABS facility while Open House attendees mingled with other members of the community, sampled our local food, beer and wine and enjoyed the live band, met with members of our Advocacy team and visited each of the member benefit booths. Click here to check out photos from the San Diego open house.
Did you miss the opportunity to celebrate with CLSA? To view the full roster of upcoming CLSA events, explore our event calendar here. To become a member, or contact us learn more about CLSA Membership here.
Pantheon 2017, CLSA Speaks at Atlantic Innovation Pipeline Program, CLSA Convenes San Diego Life Sciences Tour & Roundtable with Congressman Cárdenas, CLSA Welcomes 12 New CLSA Members, CLSI FAST Companies & CARB-X Funding, Don’t Miss the MedTech Conference or the 2017 BIO Investor Forum, and CLSA Expansion
By: Sara Radcliffe
CLSA President & CEO
CLSA – California Life Sciences Association
August 24, 2017
Secure Your Pantheon Sponsorship Today
On November 10, the California life sciences community will celebrate another year of leadership, innovation, and overall excellence at CLSA’s signature event – the 14th Annual Pantheon DiNA Awards. Don’t miss your chance to participate in this extraordinary event! Limited sponsorships and tables are still available. Contact us to attend or learn more here.
CLSA at The Atlantic Innovation Pipeline Event
On August 1, I had the pleasure of speaking about the life sciences industry and the legislative environment at The Atlantic’s Innovation Pipeline event. Attendees also got to hear from Dr. Robert Califf, Former FDA Commissioner and current Verily Life Sciences advisor, who discussed the role of big data in biotech and how researchers, clinicians and tech companies can collaborate to innovate our health systems.
Venture capital leaders Leon Cheon (OrbiMed), Carol Gallagher (New Enterprise Associates) and Andrew Schiff (Aisling Capital) explored the talent pipeline trends and other issues at the forefront for investors. Helix CEO Robin Thurston looked at developments in the personal genomics market – and how consumer demand and the FDA play into the industry’s future – and Cary Gunn (Genalyte), Sean Harper (Amgen), Gabe Otte (Freenome) and Lynn Seely (Myovant Sciences) discussed how therapeutic and diagnostic companies can collaborate to find better treatments for patients. I was so pleased to represent our state’s life sciences innovators alongside these extraordinary panelists and encourage you to learn more and watch the whole event here.
CLSA Arranges Tours & Roundtable with Congressman Cárdenas
Over three days in early August, our CLSA team arranged for Congressman Tony Cárdenas (D-San Fernando Valley) and his Washington DC-based staff to tour multiple life sciences sector companies and research institutions across the San Diego region, culminating in an innovation roundtable at JLABS with representatives from the life sciences community across San Diego. In addition to the JLABS facility, Team Cárdenas and our CLSA Federal Government Relations team visited and toured local CLSA member companies including BD, Celgene, Dexcom, JLABS and the prospective member of Scripps Research Institute (TSRI). Read here for more information.
CLSA Welcome 12 New Members in July
Please join us in welcoming the 12 new CLSA members who joined us in the last month:
BioBlocks, Bonneville Labs (previously BioDojo), Carbosynth, eResearchTechnology (ERT), MicrobeDx, Mintz Levin Cohn Ferris Glovsky and Popeo PC, Neuralink, Peregrine Biotechnology, PharmaCyte Biotech Inc., Precision Diagnostics, Seqmatic and Zenobia Therapeutics. Our membership portfolio grows ever more robust with the addition of these organizations, which add significantly to the expertise and resources available in the CLSA network.
CLSI Introduces Fall 2017 FAST Companies
We are pleased to introduce the Fall 2017 FAST Companies: BioAmp Diagnostics, developing diagnostic tools that decrease the time-to-results for identification of bacterial infections from 3 days to 30 minutes using an innovative amplification technology; Device Farm, developing a gas-based treatment to treat nail fungal infections; Inflammatix, developing a statistically rigorous, extensively validated diagnostic method that ‘reads’ the immune system; Oomni, developing a small molecule targeting bladder cancer that simultaneously addresses both the cancer and resultant pain; Pheronym, an Ag-biotech company that develops green solutions for agricultural pest control; Phi Therapeutics, developing a platform technology to enhance natural phage with payloads to improve bacterial targeting and neutralization; Siolta, altering the therapeutic landscape of inflammatory diseases through the development of live biotherapeutic products (LBP) using an ecosystems approach; and STATegics, developing small molecule agonists of the tissue-protective receptor for treatment of CNS and rare diseases.
CARB-X Round 2 Funding Awarded
CARB-X, one of the world’s largest public-private partnerships focused on combating antimicrobial resistance (AMR), recently announced its second round of funding, injecting an additional $17.6M to accelerate products for combatting antibiotic resistance. The consortium – which includes the California Life Sciences Institute (CLSI), the Wellcome Trust, BARDA, RTI International, NIAID, and MassBio, and is administered by Boston University – provides strategic business support to companies with promising early-stage technologies to develop a portfolio of innovative products to address this critical threat to global health. Learn more about CLSI’s CARB-X accelerator here.
Don’t Miss Out – Register for the 2017 MedTech Conference
September 25-27 – San Jose, CA
Join CLSA and more than 2,500 attendees at The MedTech Conference powered by AdvaMed to network, gain access to capital and share insights in San Jose, CA from September 25-27. The conference features world-class plenary speakers, networking, and business development opportunities. CLSA Members may contact us today to take advantage of our exclusive 10% CLSA discount and claim your spot for The MedTech Conference! Register or learn more here.
What Can You Expect at the 2017 BIO Investor Forum?
The 16th annual BIO Investor Forum (Oct. 17-18 in San Francisco) is the most influential independent investor event for early-stage biotechs seeking new funding sources. This year’s event will host more than 175 healthcare venture capital and public market investors and more than 600 business development executives from leading global pharmaceutical and biotechnology companies. CLSA Fellows members, contact us before September 29 to access your discounted pricing! Register or learn more here.
CLSA Is Still Growing
We’re excited to announce the continued strategic expansion of our CLSA team with the addition of two new employees this month:
Joe Teevan, Controller
Joe Teevan consulted with CLSA earlier this year through Signature Analytics and joins us as Controller. He will be based in the San Diego office and will be responsible for accounting and finance-related activities. Joe received his Bachelor of Science degree in Business Administration, Accounting from Xavier University, Cincinnati, OH. Prior to CLSA, Joe was an auditor with BDO and worked at Western Union in Colorado. Click here to learn more.
Lilia Stone, Associate, State Government Relations
Based in CLSA’s Sacramento Office, Lilia Stone will participate in the implementation of strategy, member relationship development and overall advancement of initiatives with key state and local policy makers, and manage administration for the Sacramento office. Lilia received her Bachelor of Arts degree in International Studies with a focus on Political Science from UC San Diego. She joins CLSA after serving as Legislative Aide and Scheduler for Assembly member Marie Waldron (R-Escondido). Click here to learn more.
President & CEO
California Life Sciences Association
PS – Do you have newsworthy items to submit for consideration for our monthly CLSA Bulletin? Feel free to send those tips to Elizabeth Gibson (EGibson@califesciences.org), CLSA’s Senior Director of Marketing & Programs.
CLSA Successfully Leads Effort to Defeat Bill Restricting Doctor-Industry Interactions
Sept. 19, 2017
On Sept. 11, Senate Bill 790 (McGuire) was placed on the inactive file, meaning that, while the bill is dead for this year, it will be eligible to be heard again once the legislature reconvenes in early January 2018.
SB 790 would have restricted all “gifts,” as defined, from manufacturers to physicians unless it fell under one of many, often confusing, exceptions. For instance, meals were either permitted or restricted in an education context depending on various circumstances, while “coffee or other snacks or refreshments” served at a booth were broadly exempt. Furthermore, while many expenses associated with “research projects” or clinical trials were permitted, questions remained around the status of many more associated activities, such as equipment loans and allowing free use of lab space. It was also unclear the extent to which activities performed under a “Compassionate Use” Investigational New Drug (IND) application would be permitted.
CLSA served as the lead for our industry on advocating against SB 790, and, in addition to lobbying in the Capitol, CLSA spearheaded an aggressive letter-writing campaign that resulted in over 450 letters from constituents to members of the legislature, urging opposition to the measure.
We anticipate the bill will return next year, though it is unclear how similar that bill will be to the final version of SB 790 on the record, though substantial amendments beyond that version of the bill were discussed prior to the close of the legislative session.
CLSA will continue to aggressively oppose this legislation and coordinate with fellow stakeholders both within and outside of the industry in doing so. Questions? Please contact Brett Johnson, CLSA’s Senior Director, Policy & Regulatory Affairs (BJohnson@califesciences.org).
Bill Mandating State Reporting by Drug Makers Heads to Governor
Sept. 18, 2017
Despite the best efforts of CLSA and its partner trade associations, Senate Bill 17 (Hernandez) has reached the Governor’s desk. Gov. Brown has until Oct. 13 to sign the bill for it to become law. If it’s signed, the advance notice requirements, as discussed below, would become effective on Jan. 1, 2018.
SB 17 would require, among many other things, industry to provide a 60-day advance notice of any price increase on a drug to all California public agency purchasers, health insurers, and pharmacy benefit managers (PBM) if that drug’s price has increased 16 percent or more cumulatively over the previous two calendar years, including the current year’s increase. In other words, if a company has increased the price of a 6 percent in 2016 and 7 percent in 2017, then it would have to provide a 60-day advance notice on any 2018 price increase that would account for the additional 3 percent needed to reach the 16 percent reporting threshold.
Beginning on Jan. 1, 2019, on the effective date of any price increase triggering the advance notice, the drug’s manufacturer would have to submit a host of information to the state, though the bill would allow the manufacture to withhold any information not “otherwise in the public domain or publicly available.” The information reported would then be posted publicly by the state in a manner that allows for identification of the individual drugs.
Though the bill appeared to stall after initially being put up for a vote in the Assembly, the bill quickly reached the 41 votes needed when being put back up for a vote, passing off the Assembly floor by a vote of 66-9. In a breach of Assembly decorum, its passage was accompanied by applause and several cheers from the Assembly floor. On Senate concurrence for the most recent amendments, the bill was sent to the Governor by a vote of 32-8.
CLSA continues to oppose the bill and has submitted a request to the Governor that the bill be vetoed, but we are anticipating that he will sign the bill into law. We also plan to organize a letter-writing effort for small company members. Visit www.ProtectAccessAndInnovation.org to see how patients, small businesses and life science innovators are speaking out against SB 17.
Finally, we are continuing to analyze the potential impacts of implementation of the bill on our industry, and any members who would like further information on this or anything else related to SB 17 are encourage to reach out to Brett Johnson, CLSA’s Senior Director, Policy & Regulatory Affairs (BJohnson@califesciences.org) or Oliver Rocroi, CLSA’s Senior Director, State Government Affairs (email@example.com).
Sonoma County Takes on Take Back
Sept. 14, 2017
On Sept. 12, the Sonoma Board of Supervisors held a new hearing on take back ordinance options for the County. At the Board’s last hearing on the subject in October of 2016, it had directed staff to begin drafting an ordinance for drug take back while also researching the potential need and possibility of including the disposal of sharps into the legislation.
The County staff then toured every locality throughout 2017 to promote extended producer responsibility (EPR) and the County’s pursuit of an ordinance. At the end of that process, staff determined there was unanimous support for overall drug take back legislation and a strong consensus for the inclusion of sharps. Of note, while all Cities in the County supported an ordinance on drug disposal generally, the City Council of Santa Rosa took a strong position against the possible addition of sharps disposal in any legislation.
During this month’s hearing before the Board, County Health Officer Karen Milman gave an update on the drafting process and an overview of the community discussions. She then sought direction on next steps for staff from the Board while providing a recommendation for the pursuit of take back legislation which included sharps.
While no formal vote was taken at the Board meeting, the Board gave its direction through a straw poll of its Members. This straw poll of 3-2 directed staff to move forward in drafting an ordinance and to include both the disposal of drugs and sharps. Of the 2 minority votes, both were interested in a drug take back ordinance, while one was interested in supporting the sharps inclusion but asked for more data to support the sharps inclusion. The staff stated they would bring more data and a draft ordinance including both drugs and sharps to the Board in the near future.
CLSA testified before the Board on behalf of our industry’s perspective and to clear up several misstatements made by the County.
CLSA will continue to be at the forefront in Sonoma County and anywhere these local discussions occur. For more information, please contact Reese Isbell, CLSA’s Director of Local Government and Community Relations ( firstname.lastname@example.org).
CLSA Hosts Congressman Tony Cárdenas for Life Sciences Roundtable & Company Tours
August 17, 2017
This August, CLSA hosted Congressman Tony Cárdenas (D-San Fernando Valley) and his Washington DC-based staff for 3-days of tours at multiple life sciences sector companies and research institutions across the San Diego region. Team Cárdenas and our CLSA Federal Government Relations team visited and toured local CLSA member companies including BD, Celgene, Dexcom, JLABS and prospective member The Scripps Research Institute (TSRI).
CLSA also convened a roundtable discussion with Rep. Cárdenas, CLSA Board Members, and representatives of CLSA member companies and research institutions at JLABS in San Diego. The discussion was focused around issues of critical importance to California’s biomedical R&D community, including the ecosystem for life sciences investment, innovation and job creation in our state, and the opportunities and challenges facing our sector, including NIH funding, intellectual property protections, FDA regulatory policies, and the coverage, payment and access environment. A particular point of discussion was on the political environment in Washington, D.C., and how to best position life sciences sector policies for success in a bitterly divided and gridlocked legislative environment.
Cárdenas, a member of the prestigious House Energy & Commerce Committee, expressed a keen desire to better understand the life sciences community and the innovations that CLSA members are developing, as well as issues and policies that can be especially challenging for growing companies.
Congressman Cárdenas’ tour and visit exemplifies CLSA’s efforts to provide premier educational opportunities to policymakers and thought leaders in Washington, Sacramento and locally.
CLSA proactively offers opportunities for congressional staff and Members of Congress to visit life sciences facilities throughout California.
For further information, including if you would like to host a federal, state or local legislator for similar facility visits, please contact Jenny Carey, CLSA’s Vice President of Federal Government Relations and Alliance Development (JCarey@Califesciences.org).
BioBlocks adds Leap-to-Lead™ platform to its Drug Discovery arsenal
After 10 years of developing leads for clients at BioBlocks, we have created the Leap-to-Lead™ platform to offer improved Lead Discovery outcomes. The platform includes the following three components:
- Tools for property based optimization
- Comprehensive Fragment Library: BioBlocks’ proprietary next generation 3D fragment library
- Syntheverse™: Reaction-based access to currently synthesizable compounds
This technology enables our partners to advance their drug discovery programs by providing the following benefits:
- Gain a head start on IP by accessing novel, 3D structures
- Practice the art of the possible: discover a lead in the synthetically accessible universe of compounds
- Revisit patent strategy by replacing common building blocks with new sizes and shapes
BioBlocks is currently seeking collaborations that can take advantage of the platforms’ lead generation potential. Please visit the technology page on our website to see our current successes.
BioBlocks provides medicinal chemistry services, technology and products to help our pharmaceutical customers accelerate their drug discovery programs. We unite our medicinal chemistry expertise, a cutting edge proprietary fragment library and the comprehensive search capability of our Syntheverse™ chemistry space to empower our clients to generate high quality clinical candidates with favorable pharmaceutical properties and IP positions. BioBlocks is a US company maintaining offices and laboratories in San Diego, California and Budapest, Hungary.
Fall 2017 JLABS San Diego Events
Could the advancement of new technologies leveraging data and analytics hold the key to transforming healthcare into a more patient centric and cost efficient model? Startups are innovating in areas such as data aggregation, risk stratification, outcomes reporting and even staffing standardization – all of which have the end goal of putting more focus on enhancing patient care. The progression of the value-for-service model has also sparked development of data driven solutions capable of demonstrating improvements in patient outcomes. The role of data in patient care is expanding in so many ways – come hear players in the field discuss trends, potential impact, challenges and more.
October 5 :: Meet with…MPM Capital 12:30-5:00pm :: Register Here
MPM Capital is looking for leading scientific research that addresses unmet medical needs across therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS, with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a $400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fun, a $470M fund that invests solely in oncology companies of any stage (therapeutics only – no diagnostics). Companies must have applied for a one-on-one meeting ahead of time and been approved, applications are due September 1st.
November 15 :: Excited About Your Story: Tell it like a TED Pro 9:30am-12:45pm :: Register Here
Learn inclusive business strategies on how to unleash your own innate powers and have others be excited about your story from a world famous, best communications and leadership trainer, John Bates. Bates will cover topics in this session including: why the ability to tell a compelling story is essential for startups, 5 elements of a strategic story, strategies for pitching in front of various audiences: clinical vs non-clinical vs investors, and how to embed storytelling into all aspects of your business and pitches.
Hogan Lovells combines with Collora, adding Boston office
Strategically bolstering the firm’s life sciences capabilities throughout the Northeastern U.S. and globally.
Global law firm Hogan Lovells announced today that it will combine with Collora, a Boston-based litigation/investigations firm with a strong focus in life sciences and healthcare, as well as financial services and technology. The combination became effective on September 1st, at which time all partners, lawyers, and business services members of Collora will join Hogan Lovells.
The addition of Collora enhances Hogan Lovells’ capabilities to serve clients in one of the most dynamic and growing markets in the US. Boston is home to global leaders in technology, life sciences, healthcare, and financial services. The area boasts elite academic and research institutions and world-class medical facilities. Economic development in the Boston metropolitan area is fuelled by an active financial services and investment community.
The new office will be focused on litigation and investigations with a particular emphasis on the life sciences and healthcare sectors; over time, Hogan Lovells expects to add regulatory, corporate transactions, and IP capabilities.
“The Boston region is a key strategic market in the United States. Although we have worked closely with clients in the area for years, it more recently became clear to us that there was a need for an office that had strong roots in the community,” said Hogan Lovells CEO Steve Immelt. “Collora is a firm that shares our values, our culture and our approach. We have worked with them for many clients over the years. It has highly regarded practices in litigation and investigations, with a particular focus in life sciences, which fits very well with our own practices. We also intend to focus on the financial services, technology industries and education sectors, where we already have strong practices in other markets. We are delighted to welcome the Collora team and look forward to working with them for the benefit of our clients.”
The combination provides Collora and its clients with access to a network of services and practitioners that seamlessly work to provide a cohesive client experience globally. Hogan Lovells is recognized as a global leader in life sciences and healthcare, with specialists in areas such as regulatory, intellectual property, transactions, and disputes. Together, the two firms have more than 500 lawyers practicing in the life sciences and healthcare industry.
Collora, which comprises 25 lawyers, including 15 partners, has several well-known trial advocates who represent both companies and individuals in government investigations, complex civil litigation, professional licensing and discipline matters and other litigation matters, with a particular focus on financial services, technology and the life sciences industry. The firm includes former federal and state prosecutors, judicial law clerks, law professors and a former chief justice of the Massachusetts Appeals Court.
“Hogan Lovells has a strong global reputation and offers us depth and reach that brings a new and exciting dimension to what we are able to offer our clients,” said Bill Lovett, currently the Managing Partner of Collora, and who will serve as the Office Managing Partner of the Hogan Lovells Boston office. “We looked very hard at making sure that the business and cultural fit would be right for us – for nearly thirty years our firm has been committed to serving our clients and contributing to our community. Based on many years of working together for some of the same clients, we know Hogan Lovells brings those qualities to the table across the entire firm. No other Boston firm has Hogan Lovells’ global reach. We look forward to making these skills available to our clients and to new Boston-area clients as well.”
Read the full coverage here.
CLSI and SENS Research Foundation Launch Rejuvenation Biology Collaboration
On September 11, 2017, the California Life Sciences Institute (CLSI) and SENS Research Foundation (SRF) held the first “Rejuvenation Biotechnology Showcase” at the UCSF Mission Bay Conference Center with over 100 persons in attendance. The evening included a snapshot of technologies at SRF as well as presentations from four FAST graduate companies whose technologies hold promise for addressing age-related disease.
The origins of the Showcase stem back to 2009 when SRF was launched to promote a rejuvenation biotechnology industry, sponsoring projects to assess changes that accrue at the cellular and molecular level as we age, and to develop interventions to remove damage, restore function, and thereby prevent disease. This is a “damage repair” strategy that applies the principles of regenerative medicine against aging, though SRF’s projects are broader than the stem cell and tissue engineering technologies that are typically associated with regenerative medicine. What began as support for a small number of basic research programs has expanded into backing for a variety of applied research programs.
In addition to opening remarks by Mike Kope, CEO of the SENS Research Foundation, and CLSI CEO & President, Lori Lindburg, the Showcase featured the following SENS researchers: Judy Campisi (Buck Institute), who presented on “Killing Dysfunctional Cells,” which looks at genetic techniques for eliminating unwanted cells and rejuvenating the immune system; Matthew O’Connor’s (SRF) presentation on “Engineering New Mitochondrial Genes to Restore Mitochondrial Function,” a novel approach to therapy for mitochondrial disease; Haroldo Silva’s discussion of “ALTerran,” a company developing unique therapeutics targeting ALT cancers and evaluating ALT cancer patients; Matthew Scholz’s discussion of Oisin Biotechnologies’ development of a highly precise, DNA-targeted intervention to clear senescent cells to reduce the negative effects of aging; and David Speigel (Yale University), who presented on “Glucosepane Crosslinks and Routes to Cleavage,” the Spiegel lab’s strategy for removing glucosepane crosslinks in an effort to restore damaged tissues to a youthful state.
Further along the rejuvenation biology pathway, the four FAST company presentations included: HepatX (Spring 2017) CEO, Erick Schurr’s discussion of cell therapies to replace liver transplant as a treatment for liver failure; SciBac (Fall 2016) CEO, Jeanette Mucha’s presentation on SciBac’s revolutionary live bioteherapeutics that treat and prevent antibiotic resistant disease while fortifying the human microbiome; SyntheX (Fall 2016) CEO Maria Soloveychik’s discussion of SyntheX’s disruption of cellular communication pathways to target proteins that are inaccessible via canonical screening technologies; and Eidos (Spring 2016) CEO Isabella Graef’s presentation on the company’s development of a novel therapeutic that addresses the root cause of transthyretin (TTR) amyloidosis, a slowly progressive condition characterized by the buildup of abnormal deposits of amyloid proteins in the body’s organs and tissues.
SRF and CLSI plan to seize on the significant interest generated in this launch event to embark on additional collaborations designed to highlight innovation in the rejuvenation biology field.
About SENS Research Foundation
SENS Research Foundation is a 501(c)(3) public charity that is transforming the way the world researches and treats age-related disease. The research we fund at universities around the world and at our own Research Center uses regenerative medicine to repair the damage underlying the diseases of aging. Our goal is to help build the industry that will cure these diseases.
Read the latest of CARB-X:
- CARB-X publishes first annual report. Highlighting its pipeline of 18 promising research projects with 8 new classes of antibiotics to treat the most urgent drug-resistant gram-negative bacteria. Read More
- CARB-XED, GARDP, ASM, and ESCMID hosted Antibiotic Bootcamps at ASM-ESCMID conference on antibiotic R&D Read More
- CARB-X-funded Proteus IRC’s device can see through the human body Read more
- Powered by CARB-X company Tetraphase Pharmaceuticals announces submission and validation of IV Eravacycline Marketing Authorization Application for the treatment of complicated intra-abdominal infection Read More
- Powered by CARB-X company Forge Therapeutics and its strategic alliance partner Evotec present preclinical efficacy data on Forge’s LpxC antibiotic program at the 2017 ASM/ESCMID Conference Read More
- Entasis announces $31.9 million extension of Series B financing to advance the company’s programs to treat multidrug-resistant gram-negative infections Read More
- The Global Antibiotic Research and Development Partnership (GARDP), which just received €56.6M of funding from six EU countries, the Wellcome Trust and South Africa, are planning to collaborate with CARB-X to work on breaking antibiotic resistance Read More
FAST & Fellows Round Up
Read the latest in FAST and Fellows news:
- GigaGen (FAST Spring 2015) studies published in peer-reviewed journal mAbs, on validating its novel monoclonal antibody discovery approach in mouse and human antibody repertoires Read More
- Former CLSA Fellow Alzeca, which is developing an imaging agent to help doctors detect Alzheimer’s disease at its earliest stages, announced it has raised $11 million in a Series A round of funding Read More
- Former CLSA Fellow Notable Labs, raises $10 million Series A financing to advance personalized cancer treatments Read More
- Current Fall 2017 FAST company Siolta Therapeutics chosen as J&J Innovation’s Quick Fire Challenge winner for Bugs, Drugs, and Beyond
- FAST Grad Paragon Genomics (Spring 2016) raises $8M in Series A funding Read More
- Vanguard Therapeutics (FAST Spring 2015) was just awarded a second $2M Phase-II SBIR grant
To learn more about the CLSA Fellows program – the significantly discounted membership for life science startups – click here.
The FAST (Fellows All-Star Team) Accelerator provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement, and business development specialists) will advise selected Fellows during a ten-to-twelve week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.
Genentech Science Garage Ribbon-Cutting
Genentech CEO Bill Anderson, South San Francisco Mayor Pradeep Gupta, SSFUSD school officials, Genentech volunteers, students and community supporters were on hand Tuesday September 5th at South San Francisco High School for the ribbon-cutting of the new Science Garage. The 6,900 square-foot state-of-the-art lab and classroom – part of a $7.8 million commitment from Genentech – will provide high school students with a multi-year hands-on biotech curriculum aimed at exposing students to biotech career and educational pathways.
Science Garage is part of Futurelab, a successful public-private partnership between Genentech and SSFUSD designed to build STEM competence and confidence for elementary through high school students in Genentech’s South San Francisco back yard. The program engages over 1,000 Genentech employees in providing mentoring, hands-on activities, science competition, school field trips and more for over 4,000 local students, as well as professional development for SSF high school teachers.